Humanized Monoclonal Antibody Fragment [EPC]

1434 reported adverse events

Drugs of this class: IDARUCIZUMAB

These side effects are most commonly reported by patients taking drugs of the Humanized Monoclonal Antibody Fragment [EPC] class:

# Side effect Count
0 DEATH 170
1 HAEMORRHAGE 119
2 GASTROINTESTINAL HAEMORRHAGE 81
3 CEREBRAL HAEMORRHAGE 80
4 HAEMORRHAGE INTRACRANIAL 67
5 DRUG INEFFECTIVE 64
6 MULTIPLE ORGAN DYSFUNCTION SYNDROME 62
7 ACUTE KIDNEY INJURY 48
8 SEPSIS 46
9 ISCHAEMIC STROKE 45
See all common reactions for Humanized Monoclonal Antibody Fragment [EPC]

Drugs of the Humanized Monoclonal Antibody Fragment [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 COAGULATION FACTOR INCREASED 5 0.0820
1 THROMBIN TIME ABNORMAL 3 0.0667
2 ANTICOAGULATION DRUG LEVEL INCREASED 11 0.0343
3 BASILAR ARTERY OCCLUSION 5 0.0301
4 THROMBIN TIME PROLONGED 6 0.0243
5 STROKE IN EVOLUTION 4 0.0180
6 HAEMORRHAGIC TRANSFORMATION STROKE 26 0.0173
7 ANTICOAGULATION DRUG LEVEL ABNORMAL 2 0.0134
8 VERTEBRAL ARTERY OCCLUSION 3 0.0133
9 RECTAL PERFORATION 5 0.0093
See all enriched reactions for Humanized Monoclonal Antibody Fragment [EPC]